Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
12 /100
LOW RISK
Score updated Jul 28, 2026

NVSEF — Novartis AG Dilution Risk Tracker

Track NVSEF dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NVSEF — Get alerts when the score changes →

As of July 28, 2026, Novartis AG (NVSEF) has a DilutionWatch DilutionScore of 12/100, rated LOW dilution risk. Novartis AG has a market capitalization of $275.72B, 1.91B shares outstanding.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
19
💰 Cash Runway
10
📊 Float Risk
0
⚠️ Warrant Exposure
15
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for NVSEF.
🔔 Track NVSEF — Get forecast alerts →

Market Data

Market Cap$275.72B
Shares Outstanding1.91B
Float1.82B
Cash$6.89B
Debt$47.00B
Short InterestN/A

Institutional Holdings

46.2% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
🔔 Track NVSEF for full holder detail →

Short Interest

Short Interest1.15M
Days to Cover16.5
% of Float0.1%
FINRA data as of Jul 15, 2026

Recent SEC Activity

No recent SEC insights

Recent News

No recent news

What This Means for NVSEF Shareholders

Novartis AG (NVSEF) has a DilutionScore of 12/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for NVSEF shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for NVSEF in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for NVSEF alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding NVSEF's Dilution Risk Factors

Primary Risk Drivers

The two most significant dilution risks for Novartis AG are Offering Ability and Cash Runway. Offering Ability scores at a moderate level, indicating the company has the capacity to issue new shares through public offerings or other mechanisms, which can increase share count and reduce ownership percentage for existing investors. Cash Runway also presents a notable risk, scoring higher than average, suggesting the company may be operating with limited cash reserves. This financial pressure could prompt the firm to raise capital via equity issuance, thereby diluting existing shareholders.

Factors Currently Not a Concern

Float Risk is currently at an extremely low level, indicating that the company’s publicly traded shares are not heavily concentrated among a small group of holders. Any significant shift in share distribution or large-scale insider selling could elevate this risk. Warrant Exposure and Convertible Note Risk are also low, but would increase if the company issues new warrants or convertible notes that can be converted into equity at below-market prices, potentially leading to dilution.

SEC Filings to Watch

Investors should monitor S-3 registrations, which allow companies to register securities for future sale without immediate disclosure of specific terms. An S-3 filing could signal an intent to raise capital through equity offerings. 424B5 filings are used for shelf registration statements and may indicate plans for upcoming share issuances. Item 1.01 of the 8-K reports any material events, including new equity offerings or capital structure changes. Additionally, 10-Q quarterly reports will show cash flow trends and balance sheet changes that could hint at future financing needs.

How Dilution Happens

Dilution begins when a company issues new shares to raise capital. If Offering Ability is high, it indicates the firm may proceed with such issuance. As Cash Runway declines, financial strain increases, making equity financing more likely. Once new shares are issued, either through public offerings or convertible instruments, the total number of outstanding shares rises. This expansion reduces each existing shareholder’s ownership percentage, directly diminishing their proportional stake in the company's value.

What Would Make This Worse

A worsening risk profile could occur if the company initiates a large-scale equity offering under an S-3 shelf registration or issues convertible notes or warrants at favorable terms. If cash reserves continue to decline and the firm becomes increasingly dependent on external funding, it may be forced into frequent capital raises. These actions would compound dilution effects and reduce investor confidence in share value retention.

Key Insight

Low scores are safer, and the current risk profile indicates strong protection against major dilution events, though vigilance is still required as certain triggers could rapidly escalate exposure.

How to Monitor NVSEF for Dilution Risk

What This Risk Level Means

A low dilution risk profile for Novartis AG (NVSEF) indicates that the company is operating with minimal exposure to potential dilution from equity issuance. As a large-cap operating company, NVSEF benefits from strong market positioning and financial stability, which typically reduces the need for frequent equity raises. The absence of elevated factors above 30/100 suggests that management has not engaged in risky capital structure practices such as frequent stock issuances or aggressive warrant programs. This is especially significant for large-cap firms where investors expect conservative financial strategies.

What Typically Happens Next

Companies with low dilution risk often maintain stable capital structures and rarely engage in shelf registrations or ATM programs unless under specific circumstances like major acquisitions or strategic investments. For a large-cap firm like Novartis, any shift toward increased equity issuance would likely be part of a deliberate financial strategy, such as funding R&D or paying down debt. Monitoring for changes in this pattern is critical, especially if the company begins filing shelf registration statements or initiating ATM programs, which are common indicators of evolving capital needs.

Monitoring Playbook

To track NVSEF’s dilution risk, use DilutionWatch to set up a custom alert for the company. Configure alerts for any change in DilutionScore above 20/100 or if new equity filings appear in SEC documents. Check the company's filings monthly and monitor Shelf & ATM Monitor for any recent activity. When thresholds are triggered, review the filing details to assess intent—whether it’s a routine capital raise or a sign of financial stress.

Early Warning Signals

Several specific signals may indicate worsening dilution risk. First, an increase in the number of outstanding warrants or the initiation of new warrant programs can be a red flag. Second, filing a shelf registration statement for future equity offerings suggests potential capital needs or strategic shifts. Third, a sudden drop in the company’s cash runway score to 80/100 or higher may indicate that management is preparing for or responding to liquidity concerns.

What a Positive Resolution Looks Like

A positive shift in NVSEF’s dilution risk profile would occur if the company completes a capital raise through a public offering, which improves financial flexibility and reduces reliance on equity issuance. Alternatively, if the company pays down debt or allows existing warrants to expire without renewal, it could lower the dilution risk score. Any of these actions would reflect prudent management and improved financial health.

Watch For

Any filing for new equity issuance, especially shelf registrations or ATM programs, as these often precede dilution events.

Full SEC filing analysis available with free account  →
Track NVSEF Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking NVSEF — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for NVSEF
NVSEF Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.